RECRUITING

Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Inflammation occurs in many brain diseases including Alzheimer's disease. In Alzheimer's disease, amyloid starts accumulating decades before the start of forgetfulness. Basic scientists have reported that inflammation but not amyloid is linked to forgetfulness. When people pinch a finger, it gets swollen. Similar changes occur in brain from various causes. New medications are under development to help healing and prevent permanent damages in the brain. When people pinch a finger, they can check if the injury is healing or getting worse by watching. Investigators can watch inside of the brain using a special camera called positron emission tomography (PET). It is currently possible to watch inflammation in the brain by taking pictures of a molecule called translocator protein (TSPO). But the problem is that by imaging TSPO, investigators can catch changes in more than one kind of cells. The information is not specific to each cell type. Such vague information is not useful to monitor the effect of new medications for inflammation. This proposal attempts to develop a novel method to capture changes in each of two major players in inflammation, microglia and astrocytes. To do so, investigators will take selective pictures of one cell type by using a novel imaging agent for PET. Investigators will also take PET pictures of TSPO. Investigators will process these two kinds of PET pictures using advanced mathematical methods and extract specific information on microglia and astrocytes. Our novel method will be useful to monitor new therapies to treat inflammation in brain.

Official Title

Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease

Quick Facts

Study Start:2023-01-20

Study Completion:2025-10-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05582200

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 90 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Individuals of either sex, 50-90 years of age. * Meeting research criteria for AD (McKhann, Knopman et al. 2011). * With a CDR (Morris 1993) score of 1-3. * Fluent in English or Spanish. * Have sufficient communication and comprehension ability to consent to the performance of the study or have a legally authorized representative.	* Inability to undergo MRI or PET for any reason, including severe claustrophobia. * History of large stroke or brain trauma, multiple sclerosis or other brain disorder that, in the judgment of the PI may confound the study. * Pregnancy. In women in whom the possibility of pregnancy cannot be excluded, a pregnancy test must be performed on site the morning of any PET visit and a negative result together with a physician interview are required prior to the administration or any radiopharmaceutical. * Research radiation exposure greater than 50 mSv effective dose within 12 months including radiation exposure from this study.

Inclusion Criteria

Exclusion Criteria

* Individuals of either sex, 50-90 years of age.
* Meeting research criteria for AD (McKhann, Knopman et al. 2011).
* With a CDR (Morris 1993) score of 1-3.
* Fluent in English or Spanish.
* Have sufficient communication and comprehension ability to consent to the performance of the study or have a legally authorized representative.

* Inability to undergo MRI or PET for any reason, including severe claustrophobia.
* History of large stroke or brain trauma, multiple sclerosis or other brain disorder that, in the judgment of the PI may confound the study.
* Pregnancy. In women in whom the possibility of pregnancy cannot be excluded, a pregnancy test must be performed on site the morning of any PET visit and a negative result together with a physician interview are required prior to the administration or any radiopharmaceutical.
* Research radiation exposure greater than 50 mSv effective dose within 12 months including radiation exposure from this study.

Contacts and Locations

Study Contact

Masahiro Fujita

CONTACT

7134410803

mfujita@houstonmethodist.org

Johnavon Linton

CONTACT

jlinton2@houstonmethodist.org

Study Locations (Sites)

Houston Methodist Research Institute

Houston, Texas, 77030

United States

Collaborators and Investigators

Sponsor: The Methodist Hospital Research Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-20

Study Completion Date2025-10-31

Study Record Updates

Study Start Date2023-01-20

Study Completion Date2025-10-31

Terms related to this study

Additional Relevant MeSH Terms

Alzheimer Disease
Healthy